← SynDRA
RABUSERTIB
SynDRA canonical compound SYN0037764 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | CHEK1 |
|---|
| Mechanism of action | CHK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- CHEK1 INHIBITOR
- Serine/threonine-protein kinase Chk1 inhibitor
- CHK1 inhibitor
- CHK inhibitor
- CHEK1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- FECH
- AAK1
- PAK2
- PDGFRB
- PCYT1A
- PASK
- PAK6
- PAK4
- PAICS
- NEK3
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- PDXK
- PEBP1
- PFKP
- PGRMC1
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIM2
- PIM1
- PHKG2
- NEK7
- NEK2
- PRKAR2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- LY-2603618
- IC-83
- LY2603618
- UNII-3S9L1NU6U7
- 3S9L1NU6U7
- ly2603618 IC-83
- (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea
- n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea
- LY2603618 (IC-83)
- Rabusertib [USAN:INN]
- 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea
- N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
- Rabusertib (LY2603618)
- LY2603618 - IC-83
- LY2603618(IC-83)
- Urea, N-(5-bromo-4-methyl-2-((2S)-2-morpholinylmethoxy)phenyl)-N'-(5-methyl-2- pyrazinyl)-
- (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea.
- Rabusertib [USAN]
- 1-[5-bromo-4-methyl-2-[[(2S)-morpholin-2-yl]methoxy]phenyl]-3-(5-methylpyrazin-2-yl)urea
- RABUSERTIB [INN]
- Rabusertib (USAN/INN)
- RABUSERTIB [WHO-DD]
- MLS006011026
- SCHEMBL304747
- GTPL7960
- CHEMBL3039517
- DTXSID50238417
- EX-A426
- CHEBI:124917
- BCPP000178
- BDBM50524309
- NSC761188
- NSC800860
- s2626
- ZINC70466463
- AKOS027422721
- BCP9000873
- CCG-264970
- CS-0472
Look up RABUSERTIB in the interactive SynDRA portal →